Navigation Links
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:9/22/2009

which demonstrates great potential for the stent in treating diabetic patients."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit ww
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
2. Prix Galien USA Announces 2009 Final Candidates
3. Quest Diagnostics Announces Final Tender Offer Results
4. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. University of Maryland Announces Finalists for $75K Business Plan Competition
11. Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... 17 Sigma-Aldrich (Nasdaq:,SIAL) today announced the publication ... accessible Journal of Visualized Experiments (JoVE).,This makes Sigma-Aldrich ... video,protocol to the traditional scientific publication process. Peer-reviewed,video ... to increase the,efficiency of scientific communication and with ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... to participate in the upcoming UBS Global Life,Sciences Conference ... City., D. Ashley Lee, executive vice president, chief ... present Wednesday,September 24 at 2:30 p.m., Eastern Time., ...
... BAX ), will host a quarterly conference call ... October 16, 2008, at,8:30 a.m. Eastern Time (7:30 a.m. ... (domestic) or 703-639-1156 (international). Please dial,into the call at ... call for the,operator to connect you., This call ...
Cached Biology Technology:Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 2Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMed's Peer-Reviewed Video Journal JoVE 3CryoLife to Present at UBS Global Life Sciences Conference 2Baxter International Third Quarter 2008 Financial Results Conference Call 2
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been ... banking account but can,t remember your password, site key or ... Who was your first grade teacher? Today, ... the app that will finally put an end ... – 1U TM . 1U leverages a user,s ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... 2013 EcoHealth Alliance, a nonprofit organization that focuses on ... a new SARS-like coronavirus (CoV) in Chinese horseshoe bats. ... an international group of collaborators have uncovered genome sequences of ... erupted in Asia in 2002 2003, which caused a ...
... It,s not unusual for scientists to take their cues from ... career on such cues. Rimer, an assistant professor of ... College of Engineering, is an expert in the field of ... from drug development to chemical synthesis to medical diseases such ...
... New York City Mayor Michael Bloomberg prepares to leave office, ... health policies and concludes that he is an urban innovator ... infectious diseases to upstream risk factors in everyday life and ... Hastings Center Report . , Lawrence O. Gostin, University ...
Cached Biology News:New SARS-like coronavirus discovered in Chinese horseshoe bats 2New SARS-like coronavirus discovered in Chinese horseshoe bats 3New SARS-like coronavirus discovered in Chinese horseshoe bats 4Taking a cue from nature 2Bloomberg's health legacy: Urban innovator or meddling nanny? 2Bloomberg's health legacy: Urban innovator or meddling nanny? 3